Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Imagine ... all the possibilities

<< Previous

Bullboard Posts

Next >>

Comment by Beanie28on Mar 07, 2021 7:32pm

222 Views

Post# 32740338

RE:RE:RE:RE:RE:RE:RE:Imagine ... all the possibilities

I've been following Antibe since 2015 man the up and downs are an emotional roller coaster and I don't have has as much as I assume you have. I do t know how you do it. My stress/grey hairs have multipled hugely I'm getting better at seeing them unrealized gains come off tho. I don't believe in the long term game will be fruitful tho

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program